Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioDelivery Sciences International, Inc. stock logo
BDSI
BioDelivery Sciences International
$5.59
$5.58
$2.50
$5.62
$577.05M0.563.34 million shs2.09 million shs
BioSpecifics Technologies Corp. stock logo
BSTC
BioSpecifics Technologies
$88.53
$88.47
$42.00
$89.15
$650.25M0.2461,105 shsN/A
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
$2.00
+0.3%
$1.64
$1.17
$21.92
$12.08M0.041.22 million shs300,875 shs
G1 Therapeutics, Inc. stock logo
GTHX
G1 Therapeutics
$7.15
$7.13
$1.08
$7.19
$373.81M1.661.70 million shsN/A
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
$6.36
+3.2%
$6.07
$5.41
$23.48
$533.30M0.41.27 million shs2.11 million shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioDelivery Sciences International, Inc. stock logo
BDSI
BioDelivery Sciences International
0.00%0.00%0.00%0.00%0.00%
BioSpecifics Technologies Corp. stock logo
BSTC
BioSpecifics Technologies
0.00%0.00%0.00%0.00%0.00%
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
-0.50%+3.63%+2.04%+21.95%-88.43%
G1 Therapeutics, Inc. stock logo
GTHX
G1 Therapeutics
0.00%0.00%0.00%0.00%+168.80%
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
+6.02%+6.02%-8.47%+9.41%-70.10%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BioDelivery Sciences International, Inc. stock logo
BDSI
BioDelivery Sciences International
N/AN/AN/AN/AN/AN/AN/AN/A
BioSpecifics Technologies Corp. stock logo
BSTC
BioSpecifics Technologies
N/AN/AN/AN/AN/AN/AN/AN/A
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
4.1294 of 5 stars
3.34.00.04.50.61.70.6
G1 Therapeutics, Inc. stock logo
GTHX
G1 Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
4.5516 of 5 stars
4.43.00.04.71.90.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioDelivery Sciences International, Inc. stock logo
BDSI
BioDelivery Sciences International
0.00
N/AN/AN/A
BioSpecifics Technologies Corp. stock logo
BSTC
BioSpecifics Technologies
0.00
N/AN/AN/A
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
2.67
Moderate Buy$42.602,030.00% Upside
G1 Therapeutics, Inc. stock logo
GTHX
G1 Therapeutics
2.00
HoldN/AN/A
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
2.86
Moderate Buy$24.50285.22% Upside

Current Analyst Ratings Breakdown

Latest KURA, BTAI, BDSI, GTHX, and BSTC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/26/2025
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight
6/20/2025
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$36.00
6/4/2025
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$28.00
5/19/2025
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$32.00 ➝ $30.00
5/2/2025
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$32.00 ➝ $11.00
4/29/2025
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$28.00 ➝ $28.00
4/28/2025
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$40.00 ➝ $40.00
(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioDelivery Sciences International, Inc. stock logo
BDSI
BioDelivery Sciences International
$166.70M3.46$0.36 per share15.42$1.90 per share2.94
BioSpecifics Technologies Corp. stock logo
BSTC
BioSpecifics Technologies
$38.19M17.03$3.38 per share26.18$18.42 per share4.81
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
$1.85M6.54N/AN/A($30.01) per share-0.07
G1 Therapeutics, Inc. stock logo
GTHX
G1 Therapeutics
$58.20M6.42N/AN/A$0.68 per share10.51
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
$53.88M10.22N/AN/A$5.32 per share1.20
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioDelivery Sciences International, Inc. stock logo
BDSI
BioDelivery Sciences International
$84.86M$0.836.748.47N/A50.90%21.25%10.56%N/A
BioSpecifics Technologies Corp. stock logo
BSTC
BioSpecifics Technologies
$24.47M$3.3337.5117.60N/A47.43%14.81%14.46%N/A
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
-$59.60M-$13.55N/AN/AN/A-2,163.18%N/A-83.80%8/5/2025 (Estimated)
G1 Therapeutics, Inc. stock logo
GTHX
G1 Therapeutics
-$47.97M-$0.62N/AN/AN/A-76.93%-136.98%-39.33%N/A
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
-$173.98M-$2.10N/AN/AN/AN/A-43.62%-29.13%8/6/2025 (Estimated)

Latest KURA, BTAI, BDSI, GTHX, and BSTC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025Q2 2025
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
-$2.30N/AN/AN/A$0.21 millionN/A
5/12/2025Q1 2025
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
-$2.72-$1.50+$1.22-$1.50$0.35 million$0.17 million
5/1/2025Q1 2025
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
-$0.51-$0.66-$0.15-$0.66$39.08 million$14.11 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BioDelivery Sciences International, Inc. stock logo
BDSI
BioDelivery Sciences International
N/AN/AN/AN/AN/A
BioSpecifics Technologies Corp. stock logo
BSTC
BioSpecifics Technologies
N/AN/AN/AN/AN/A
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
N/AN/AN/AN/AN/A
G1 Therapeutics, Inc. stock logo
GTHX
G1 Therapeutics
N/AN/AN/AN/AN/A
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioDelivery Sciences International, Inc. stock logo
BDSI
BioDelivery Sciences International
0.29
2.45
2.17
BioSpecifics Technologies Corp. stock logo
BSTC
BioSpecifics Technologies
N/A
66.24
66.24
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
N/A
1.48
1.45
G1 Therapeutics, Inc. stock logo
GTHX
G1 Therapeutics
1.34
2.48
2.12
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
0.02
8.07
8.07
CompanyEmployeesShares OutstandingFree FloatOptionable
BioDelivery Sciences International, Inc. stock logo
BDSI
BioDelivery Sciences International
200103.23 million92.93 millionOptionable
BioSpecifics Technologies Corp. stock logo
BSTC
BioSpecifics Technologies
77.35 millionN/ANot Optionable
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
906.06 million4.77 millionOptionable
G1 Therapeutics, Inc. stock logo
GTHX
G1 Therapeutics
17052.28 million49.09 millionOptionable
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
13086.57 million81.03 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BioDelivery Sciences International stock logo

BioDelivery Sciences International NASDAQ:BDSI

BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; and Symproic, a peripherally acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation. The company also provides ELYXYB, a celecoxib oral solution for the treatment of migraine with or without aura in adults; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in cancer patients. BioDelivery Sciences International, Inc. was incorporated in 1997 and is headquartered in Raleigh, North Carolina. As of March 18, 2022, BioDelivery Sciences International, Inc. operates as a subsidiary of Collegium Pharmaceutical, Inc.

BioSpecifics Technologies stock logo

BioSpecifics Technologies NASDAQ:BSTC

BioSpecifics Technologies Corp., a biopharmaceutical company, develops an injectable collagenase clostridium histolyticum for various indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX and Xiapex brands. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis, human lipoma, and uterine fibroids. The company has a development and license agreement with Endo Global Ventures. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Wilmington, Delaware.

BioXcel Therapeutics stock logo

BioXcel Therapeutics NASDAQ:BTAI

$2.00 +0.01 (+0.25%)
Closing price 04:00 PM Eastern
Extended Trading
$2.07 +0.07 (+3.70%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.

G1 Therapeutics stock logo

G1 Therapeutics NASDAQ:GTHX

G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing Trilaciclib that is in Phase 3 clinical trial for 1L metastatic triple negative breast cancer (mTNBC); and Phase 2 clinical trial as an antibody-drug conjugate combination trial in mTNBC, as well as completed Phase 2 clinical trial for Neoadjuvant TNBC and 1L Bladder cancer. The company has a license agreement with Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat various indication in humans; Incyclix for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses; and Simcere Pharmaceutical Co., Ltd for the development and commercialization of trilaciclib in all indications. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.

Kura Oncology stock logo

Kura Oncology NASDAQ:KURA

$6.36 +0.20 (+3.25%)
Closing price 04:00 PM Eastern
Extended Trading
$6.32 -0.04 (-0.55%)
As of 07:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.